The thermosensitive growth phenotype exerted by runaway-mutant plasmids was suppressed by sublethal doses of the DNA gyrase inhibitors novobiocin or nalidixic acid, although the latter drug was less efficient. A novobiocin-resistant gyrB mutant Escherichia coli strain prevented expression of the runaway phenotype at 37 to 42°C in the absence of any drug.
We have earlier described a runaway-replication plasmid mutant of the R-plasmid Rldrd-19 which replicates without copy number control when the host bacteria are grown at temperatures above 35°C (17, 19) . Since runaway replication eventually results in inhibition of host-cell growth, one would expect that conditions which somehow reduce the rate of plasmid synthesis might suppress the thermosensitive phenotype.
In Escherichia coli the enzyme DNA gyrase introduces negative superhelical turns into DNA (2, 6, 7) . The degree of DNA supercoiling in E. (oli seems to depend on a dynamic balance between two mutually antagonistic enzyme activities: DNA gyrase which supercoils DNA, and DNA topoisomerase I and perhaps other enzymes which remove supercoils (4, 15) . In preliminary experiments with the gyrase inhibitor novobiocin, we found that the presence of a sublethal dose of the drug in the growth medium resulted in suppression of the thermosensitive phenotype exerted on the host cells by the runaway-mutant plasmids (9) . To analyze the effect of different gyrase inhibitors in more detail, E. coli C600 carrying the runaway-mutant pKN401 (19) or the wild-type plasmid Rldrd-19 (12) was cultivated in LB-medium and maintained as described earlier (18, 19) . Cultures at 30°C, grown in the exponential growth phase for at least six cell doublings, were diluted and plated on LA-plates containing 25 p.g of chloramphenicol per ml and different concentrations of novobiocin. The plating efficiencies at 30, 37, and 42°C were monitored by colony counts after incubation over night (Table 1) . Plating efficiency of strain C600(pKN401) at 37 or 42°C was restored to about 40 to 70% of the novobiocin-free control at 30°C when the bacteria were plated in the presence of 50 to 100 ,ug of novobiocin per ml. Since addition of the drug reduced plating efficiency of this strain also at 30°C, the viability was about the same at all three temperatures for novobiocin concentrations of 50 to 100 p.g/ml. The phenotype at 37°C when nalidixic acid concentrations of about 2 to 3 pg/ml were used for strain C600(pKN401). However, very few colonies were obtained at 42°C, and the extent of suppression varied considerably between different experiments. The colonies at 37 and 42°C were much smaller than those at 30'C, and it was evident that the cells grew very slowly at higher temperatures.
Treatment of strain C600(pKN401) with novobiocin while the cells were growing in liquid culture gave results similar to those obtained in the plating tests described above (data not shown); in the absence of the drug, a temperature shift from 30 and 40°C resulted in inhibition of cell growth after about 2 h at the postshift temperature as a consequence of runaway-plasmid replication. Addition of 75 Vsg of novobiocin per ml after the shift prevented the growth inhibition, and the C600(pKN401) cells continued to grow in a manner indistinguishable from that of the control strain C600(Rldrd- 19) .
To study directly the effect of novobiocin on plasmid synthesis, we carried out temperature-shift experiments in which the DNA was radioactively labeled by [methyl3Hlthymidine incorporation as described earlier (19) . The uptake of trichloroacetic acid-precipitable label by a culture of C600(pKN401) was determined during a shift from 30 to 40°C. After 25 min at 400C, the culture was divided into two parts and 75 pg of novobiocin per ml was added to one part. Total DNA synthesis in the drug-free culture leveled off after about 2 h, whereas DNA synthesis of the novobiocin-treated culture continued with a slightly adjusted rate throughout the experiment (data not shown). At selected times, samples from the two cultures were taken, and after subsequent (19) , the relative amount of plasmid DNA was estimated (Table 2) . Evidently, the treatment with novobiocin resulted in a direct partial inhibition of plasmid DNA synthesis such that the cells, on the average, contained the same relative amount of plasmid as before the temperature shift. Plasmid synthesis was not completely inhibited by the drug, but the frequency with which plasmid replication initiated appeared identical to the preshift frequency.
Since there was a possibility that novobiocin exerted its effect upon runaway replication by acting on a target different from the gyrB gene product, e.g., an unknown plasmidencoded gyrase analog, we wanted to carry out control experiments in a novobiocin-resistant gyrB mutant host strain. Therefore, we introduced the two runaway-plasmid derivatives (20) pBEU1 and pBEU2 into strain NI748, which has been characterized biochemically with respect to DNA gyrase and has been shown to produce a novobiocin-resistant enzyme due to a mutation in the gyrB gene (8) . Cultures grown at 30°C were assayed for plating efficiency at 30 and 42°C on plates containing novobiocin or coumermycin ( Table 3) . Surprisingly, we found that the gyrB mutant strain by itself prevented expression of the runaway-mutant phenotype. Without addition of the drug, the plasmid-containing N1748 cells retained between 25 and 100% plating efficiency at 42°C (Table 3) . AT 30°C strain N1748 grew on novobiocin concentrations as high as 500 ,ug/ml irrespective of whether it carried the runaway plasmids. However, in the presence of novobiocin, the viable counts of the plasmid-carrying derivatives N1748(pBEU1) and N1748(pBEU2) were clearly reduced at 42°C. The susceptibility to the analogous drug coumermycin was also higher at 42 than at 30°C. The results of the experiment did not rule out the possibility that novobiocin might act also on some plasmid-encoded component. However, the fact that the mutant strain suppressed the runaway phenotype in the absence of any drug shows that the host-cell DNA gyrase has a function in synthesis of the plasmids.
Suppression of the runaway phenotype has also been observed in preliminary experiments with another kind of gyrB mutant; a strain carrying the gyrBII4 allele (formerly called himB114 [13] ) prevented expression of the runaway phenotype, whereas an otherwise isogenic gyrB+ strain did not (B. E. Uhlin, unpublished data). The gyrB14 mutation was not originally defined as causing drug resistance but was identified as a mutation preventing phage lambda site-specific recombination (13) . Recently, two mutations in gyrB, which produce a temperature-sensitive Him-phenotype were shown to cause curing of the plasmids pBR322 and (21) . Furthermore, the supercoiling of plasmids was found to be altered in cells treated in vivo with the DNA gyrase inhibitors novobiocin and oxolinic acid (10) . The present system with runaway replication provided direct evidence for the hypothesis that curing by novobiocin is exerted at the level of plasmid DNA replation rather than segregation as discussed by Wolfsp et al. (22) . The results are also consistent with tje observed inhibitory effect by novobiocin on in vitro plasmid replication (14) . It remains to be elucidated how interference with DNA gyrase activity may cause a preferential effect upon plasmid DNA replication. Although the runaway-mutant plasmids may not necessarily reflect the behavior of nonmutant plasmids, this system should be useful for further studies of this kind of host-plasmid interactions. The method of suppressing the therm'oensensitive phenotype by novobiocin treatment has proven valuable in application with cloning vector derivatives of the runaway mutant and in isolation of new derivatives (16, 20 
